Nami Surgical, a company aiming to transform the robotic-assisted surgery market with a breakthrough ultrasonic platform, has secured $4 million of investment and grant funding. St Andrews-based impact investment firm Eos Advisory led the seed $3.1 million round alongside the Investment Fund for Scotland, which is managed by UK private equity firm Maven and delivered by British Business Bank, Scottish Enterprise, and SIS Ventures. The company was also separately awarded a grant from Innovate UK, the United Kingdom’s national innovation agency.
Nami Surgical develops miniaturized ultrasonic medical devices for surgical applications and supports medical device companies in delivering innovation in ultrasonic surgery. Nami has introduced a high-performance, miniaturized ultrasonic scalpel, overcoming significant barriers in robotic-assisted surgery. Traditionally favored in laparoscopic procedures, ultrasonic scalpels have been too large for effective use in robotic surgery until now.
Robotic surgeries significantly reduces patient trauma, post-operative pain, and recovery times, leading to shorter hospital stays. And as robotic surgery becomes the standard for various procedures, its global market is set to quadruple, reaching approximately $36 billion by 2032. With Nami’s pioneering technology, integrating ultrasonic scalpels in robotic surgeries sets a new benchmark in surgical care, promising improved outcomes for patients worldwide.
The company was co-founded by CTO Dr Rebecca Cleary in 2022 and it is chaired by experienced life science and medtech NXD Albert Nicholl.
KEY QUOTES:
“Robot-assisted surgery has become increasingly popular in recent years and is now widely used in various surgical procedures including urology, gynaecology, and colorectal. We have pilot programs running with healthcare and medical device groups worldwide, including in the United States, and we now look forward to the commercialization phase with the support of our new investors.”
“We are committed to close collaboration with clinicians and companies in the industry to translate their needs into novel devices that not only improve patient outcomes but also drive ultrasonic surgery to the next level. It’s an exciting time for us, and we are just getting started.”
- Nami Surgical’s CEO and Co-founder Nico Fenu
“We have a huge opportunity ahead of us and a fast route to market with the first product from the platform.”
- Albert Nicholl
